Cullinan Therapeutics, Inc.CGEMNASDAQ

Overview Intelligence Charts News Fundamentals Key Metrics Earnings Growth Financials Insiders

Latest News

defenseworld.net

Cullinan Therapeutics flags 2026 as “defining year” at Leerink, tees up key CLN-978/CLN-049 data

Cullinan Therapeutics (NASDAQ: CGEM) outlined a milestone-heavy roadmap during a presentation at Leerink Partners' Annual Healthcare Conference in Miami, with management emphasizing 2026 as a potentially "defining year" driven by multiple clinical readouts across its pipeline. Chief Executive Officer Nadim and Chief Medical Officer Jeff highlighted two "high-priority" T-cell engager (TCE) programs-CLN-978 in autoimmune diseases and

globenewswire.com

Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA confirmed for Q3 2026 Zipalertinib rolling NDA submission completed; enrollment of REZILIENT3 frontline study completed with top-line results available by year-end 2026 Cash and investments of $439.0 million as of December 31, 2025; runway into 2029 CAMBRIDGE, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today provided an update on recent and anticipated business highlights and announced its financial results for the fourth quarter and full year ended December 31, 2025.

defenseworld.net

Cullinan Therapeutics Maps 2026 Data Catalysts for Autoimmune CLN-978, AML CLN-049 at TD Cowen Conference

Cullinan Therapeutics (NASDAQ: CGEM) executives highlighted upcoming clinical milestones for the company's two high-priority T-cell engager programs during remarks at the 46th Annual TD Cowen Healthcare Conference, pointing to multiple data readouts in autoimmune disease in 2026 and an expansion plan for its acute myeloid leukemia (AML) program. Management frames 2026 as a catalyst year President

defenseworld.net

Nadim Ahmed Sells 16,381 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock

Cullinan Therapeutics, Inc. (NASDAQ: CGEM - Get Free Report) CEO Nadim Ahmed sold 16,381 shares of the business's stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $13.62, for a total transaction of $223,109.22. Following the transaction, the chief executive officer directly owned 404,318 shares in

defenseworld.net

Jennifer Michaelson Sells 11,742 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock

Cullinan Therapeutics, Inc. (NASDAQ: CGEM - Get Free Report) insider Jennifer Michaelson sold 11,742 shares of the business's stock in a transaction on Friday, February 20th. The stock was sold at an average price of $14.08, for a total transaction of $165,327.36. Following the completion of the sale, the insider directly owned 181,977 shares of the

globenewswire.com

Cullinan Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced its participation in the following upcoming investor conferences: Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D.

seekingalpha.com

Cullinan Therapeutics: Thesis Strengthening For This T-Cell Engager Specialist

Cullinan Therapeutics is rated a Buy, driven by a robust T-cell engager pipeline, savvy management, and a strong $430M+ cash position. CLN-049 (FLT3xCD3) shows ~30% CR rates in AML, with broad applicability, favorable safety, and a clear accelerated approval path via single-arm study. A clear path to market for CLN-049 and regulatory precedent set by predecessors in AML increase the attractiveness of this setup, along with long-lived IP.

seekingalpha.com

Cullinan Therapeutics, Inc. (CGEM) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

defenseworld.net

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Cullinan Therapeutics, Inc. (NASDAQ: CGEM - Get Free Report) has been given an average recommendation of "Moderate Buy" by the ten analysts that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has assigned a strong buy

globenewswire.com

Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit

CAMBRIDGE, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D.

defenseworld.net

Cullinan Therapeutics Tees Up Catalyst-Heavy 2026 With Q2 CLN-978 Data and AML Fast Track Momentum

Cullinan Therapeutics (NASDAQ: CGEM) expects 2026 to be a catalyst-heavy year across its pipeline, led by two "high-priority" T-cell engager programs in autoimmune disease and acute myeloid leukemia (AML), according to comments from CEO Nadim Ahmed and Chief Medical Officer Jeffrey Jones during a Guggenheim fireside chat. Ahmed said the company laid out milestones "starting from

globenewswire.com

Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026

CAMBRIDGE, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D.

seekingalpha.com

Cullinan Therapeutics: Cash-Rich Biotech With Multiple Value Drivers

Cullinan Therapeutics is a cash-rich clinical-stage biotech with great autoimmune and AML T-cell research, which has promising catalysts for 2026. CGEM also partnered for zipalertinib, which is nearing NDA completion in Q1 2026. I believe this program alone could quickly unlock considerable shareholder value. Additionally, CGEM's CLN-978 (CD19xCD3) will enter Phase 1 and is progressing well as a potential long-term core value driver post-zipalertinib.

globenewswire.com

Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones

Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data Company to complete monotherapy expansion cohorts to determine recommended Phase 2 dose for CLN-049 pivotal registrational study and initiate combination study in frontline AML in Q4 2026 Zipalertinib rolling NDA submission expected to be complete in Q1 2026 and full enrollment of REZILIENT3 frontline study expected in H1 2026 Preliminary cash and investments of $439.0 million as of December 31, 2025; Runway into 2029 CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today provided a corporate update and shared anticipated business highlights for 2026.

defenseworld.net

Cullinan Therapeutics (NASDAQ:CGEM) Trading 3.9% Higher – What’s Next?

Shares of Cullinan Therapeutics, Inc. (NASDAQ: CGEM - Get Free Report) shot up 3.9% during trading on Wednesday. The stock traded as high as $10.22 and last traded at $10.31. 419,488 shares traded hands during mid-day trading, a decline of 37% from the average session volume of 661,582 shares. The stock had previously closed at

defenseworld.net

Cullinan Therapeutics (NASDAQ:CGEM) versus Precision BioSciences (NASDAQ:DTIL) Critical Analysis

Cullinan Therapeutics (NASDAQ: CGEM - Get Free Report) and Precision BioSciences (NASDAQ: DTIL - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation. Risk and Volatility Cullinan Therapeutics has a

defenseworld.net

Assenagon Asset Management S.A. Has $1.05 Million Stake in Cullinan Therapeutics, Inc. $CGEM

Assenagon Asset Management S.A. raised its stake in shares of Cullinan Therapeutics, Inc. (NASDAQ: CGEM) by 1,665.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 177,685 shares of the company's stock after buying an additional 167,623 shares during the period. Assenagon

defenseworld.net

Cullinan Therapeutics (NASDAQ:CGEM) Insider Jennifer Michaelson Sells 1,345 Shares

Cullinan Therapeutics, Inc. (NASDAQ: CGEM - Get Free Report) insider Jennifer Michaelson sold 1,345 shares of the firm's stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $10.01, for a total value of $13,463.45. Following the completion of the sale, the insider directly owned 132,635 shares of the

defenseworld.net

Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells $28,023.66 in Stock

Cullinan Therapeutics, Inc. (NASDAQ: CGEM - Get Free Report) insider Jennifer Michaelson sold 2,898 shares of the firm's stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $9.67, for a total value of $28,023.66. Following the completion of the sale, the insider owned 133,980 shares of the company's

seekingalpha.com

Cullinan Therapeutics, Inc. (CGEM) Discusses Initial CLN-049 Results and Development Strategy for AML Applications Transcript

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance